Zeeshan H. Syedain
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Zeeshan H. Syedain has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
Mariah McMahon
Vascudyne Inc, Saint Paul, USA
4 shared publications- Robert T. Tranquillo
Department of Biomedical Engineering, University of Minnesota, Minneapolis, USA
4 shared publications Abrielle Krouse
Vascudyne Inc, Saint Paul, USA
2 shared publicationsAbrielle Prunty
Vascudyne Inc, St Paul, USA
2 shared publicationsAdrian Ebner
Sanatorio Italiano Hospital, Asunción, Paraguay
2 shared publications- Gurumurthy Hiremath
Medical School, University of Minnesota, Minneapolis, Minnesota, USA
2 shared publications
Latest Publications
- Open Access
- 21 August 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 9991
18 Month patency of acellular bioengineered regenerative conduit as coronary artery bypass
Coronary artery bypass grafting remains the standard of care for complex coronary artery disease; however, outcomes are limited by failure or lack of suitable native vessels. Tissue-engineered vascular grafts have shown promise in peripheral applications, yet durable performance in coronary circulation remains unmet. In this study, tissue-engineered vessels are implanted with and without external support as coronary artery bypass grafts in an ovine model and anticoagulants are administered for 180 days. Unsupported vessels fail early due to kink-related thrombus, whereas external supported vessels achieve 100% patency at 180 days. Further, two animals are followed through 550 days without anticoagulant to maintain patency. The tissue engineered vessel explants demonstrate host-mediated remodeling including endothelium, no thrombus, minimal inflammatory response, and burst pressures exceeding native coronary bypass grafts. This study demonstrates preliminary, long-term patency after withdrawal of anticoagulation, with evidence of regenerative transformation into a living, functional vessel.
- 21 August 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 9991
Open Access18 Month patency of acellular bioengineered regenerative conduit as coronary artery bypass
Coronary artery bypass grafting remains the standard of care for complex coronary artery disease; however, outcomes are limited by failure or lack of suitable native vessels. Tissue-engineered vascular grafts have shown promise in peripheral applications, yet durable performance in coronary circulation remains unmet. In this study, tissue-engineered vessels are implanted with and without external support as coronary artery bypass grafts in an ovine model and anticoagulants are administered for 180 days. Unsupported vessels fail early due to kink-related thrombus, whereas external supported vessels achieve 100% patency at 180 days. Further, two animals are followed through 550 days without anticoagulant to maintain patency. The tissue engineered vessel explants demonstrate host-mediated remodeling including endothelium, no thrombus, minimal inflammatory response, and burst pressures exceeding native coronary bypass grafts. This study demonstrates preliminary, long-term patency after withdrawal of anticoagulation, with evidence of regenerative transformation into a living, functional vessel.
- Open Access
- 15 April 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (8) , 3003
First European Clinical Implant of an Off-the-Shelf Bioengineered Blood Vessel for Coronary Artery Bypass
Background: Coronary artery bypass grafting is the optimal revascularization strategy for patients with complex multivessel coronary artery disease. However, saphenous vein grafts are associated with high failure rates and donor site morbidity. Off-the-shelf tissue-engineered vascular grafts offer a potential solution for patients lacking suitable autologous vessels. Here, we report the first successful clinical implant of an acellular Tissue-Engineered Vessel (TEV) for coronary artery bypass grafting in Europe. Methods: A 73-year-old male with two-vessel disease and no suitable autologous vein underwent on-pump coronary artery bypass grafting using the left internal mammary artery to the left anterior descending artery and a 4 mm TEV to the right coronary artery. Results: Implant procedure followed standard surgical techniques, sutures and duration. The conduit handling was comparable to native vessels. Intraoperative flow measurements demonstrated excellent graft performance (TEV: 110 mL/min, Pulsatility Index 1.0). Postoperative recovery was uneventful. One-month computed tomography coronary angiography confirmed graft patency. Discussion: This case demonstrates the feasibility of using a bioengineered conduit for coronary revascularization in patients without suitable autologous grafts. If these findings are confirmed in larger trials, bioengineered vessels could expand surgical revascularization to patients without suitable autologous conduits and fundamentally alter conduit selection strategy in CABG. Conclusions: This first-in-Europe clinical implant demonstrates that an off-the-shelf acellular tissue-engineered vessel can meet the procedural, hemodynamics, and patency requirements of coronary artery bypass. These proof-of-concept results support progression to prospective multi-center evaluation.
- 15 April 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (8) , 3003
Open AccessFirst European Clinical Implant of an Off-the-Shelf Bioengineered Blood Vessel for Coronary Artery Bypass
Background: Coronary artery bypass grafting is the optimal revascularization strategy for patients with complex multivessel coronary artery disease. However, saphenous vein grafts are associated with high failure rates and donor site morbidity. Off-the-shelf tissue-engineered vascular grafts offer a potential solution for patients lacking suitable autologous vessels. Here, we report the first successful clinical implant of an acellular Tissue-Engineered Vessel (TEV) for coronary artery bypass grafting in Europe. Methods: A 73-year-old male with two-vessel disease and no suitable autologous vein underwent on-pump coronary artery bypass grafting using the left internal mammary artery to the left anterior descending artery and a 4 mm TEV to the right coronary artery. Results: Implant procedure followed standard surgical techniques, sutures and duration. The conduit handling was comparable to native vessels. Intraoperative flow measurements demonstrated excellent graft performance (TEV: 110 mL/min, Pulsatility Index 1.0). Postoperative recovery was uneventful. One-month computed tomography coronary angiography confirmed graft patency. Discussion: This case demonstrates the feasibility of using a bioengineered conduit for coronary revascularization in patients without suitable autologous grafts. If these findings are confirmed in larger trials, bioengineered vessels could expand surgical revascularization to patients without suitable autologous conduits and fundamentally alter conduit selection strategy in CABG. Conclusions: This first-in-Europe clinical implant demonstrates that an off-the-shelf acellular tissue-engineered vessel can meet the procedural, hemodynamics, and patency requirements of coronary artery bypass. These proof-of-concept results support progression to prospective multi-center evaluation.
- Open Access
- 19 March 2026
- Published by Elsevier in JACC: Case Reports
- Vol. 31 (16) , 107487
Clinical Evaluation of Completely Biological Engineered Vessel for Coronary Artery Bypass
- 19 March 2026
- Published by Elsevier in JACC: Case Reports
- Vol. 31 (16) , 107487
Open AccessClinical Evaluation of Completely Biological Engineered Vessel for Coronary Artery Bypass
- Open Access
- 1 January 2025
- Published by SAGE Publications in Journal of the Heart Valve Society
- Vol. 2 (1) , 15-26
18-Month Implant of a Transcatheter Pulmonary Valve Using Bioengineered Tissue Leaflets in Juvenile Sheep
Congenital valve disease, predominantly in the pulmonary position, requires multiple replacements as current bioprosthetic valves degrade and calcify over time. An allogenic, decellularized bioengineered tissue with minimum immune response and calcification would provide an ideal solution for young patients and could substantially improve the standard of care. In this study, a transcatheter pulmonary valve with bioengineered tissue leaflets on a self-expanding nitinol stent was implanted for up to 18 months in five juvenile sheep using an 18Fr transapical delivery system. Serial echo monitoring showed an increase in cardiac output as the juvenile sheep grew without any decrease in effective orifice area (>2 cm 2 ) or increase in pressure gradients (<10 mmHg for both peak and mean). No valvular regurgitation, leaflet thickening, or tissue abnormality was reported at any time points. Micro-CT and histological assessment showed mild calcification and mild thrombosis. The 18-month implants in the highly calcific juvenile sheep model showed no loss of function and no deterioration of the bioengineered tissue, suggesting a suitable alternative leaflet material for younger patients where functional longevity is critical.
- 1 January 2025
- Published by SAGE Publications in Journal of the Heart Valve Society
- Vol. 2 (1) , 15-26
Open Access18-Month Implant of a Transcatheter Pulmonary Valve Using Bioengineered Tissue Leaflets in Juvenile Sheep
Congenital valve disease, predominantly in the pulmonary position, requires multiple replacements as current bioprosthetic valves degrade and calcify over time. An allogenic, decellularized bioengineered tissue with minimum immune response and calcification would provide an ideal solution for young patients and could substantially improve the standard of care. In this study, a transcatheter pulmonary valve with bioengineered tissue leaflets on a self-expanding nitinol stent was implanted for up to 18 months in five juvenile sheep using an 18Fr transapical delivery system. Serial echo monitoring showed an increase in cardiac output as the juvenile sheep grew without any decrease in effective orifice area (>2 cm 2 ) or increase in pressure gradients (<10 mmHg for both peak and mean). No valvular regurgitation, leaflet thickening, or tissue abnormality was reported at any time points. Micro-CT and histological assessment showed mild calcification and mild thrombosis. The 18-month implants in the highly calcific juvenile sheep model showed no loss of function and no deterioration of the bioengineered tissue, suggesting a suitable alternative leaflet material for younger patients where functional longevity is critical.
- Open Access
- 16 October 2024
- Published by Springer Nature in Communications Medicine
- Vol. 4 (1) , 1-12
Evaluation of an engineered vascular graft exhibiting somatic growth in lambs to model repair of absent pulmonary artery branch
Background Growth is the holy grail of tissue implants in pediatrics. No vascular graft currently in use for surgical repairs of congenital heart defects has somatic growth capacity. Methods Biologically-engineered grafts (6 mm) grown from donor ovine fibroblasts in a sacrificial fibrin gel were implanted into the left pulmonary branch of 3-month old lambs for 3, 6, and 18 months. A control group of Propaten® PTFE grafts was implanted for 6 months. Results The engineered grafts exhibit extensive site-appropriate recellularization after only 3 months and near-normal increase of diameter from the preimplant value of 6 mm to 12.9 mm and also a doubling of length from 6.0 mm to 13.0 mm at 6 months (n = 3) associated with apparent somatic graft growth (collagen content increase of 265% over 18-month, n = 2), along with excellent hemodynamics and no calcification, in contrast to the Propaten® grafts. The left-right flow distribution is nearly 50–50 for the engineered grafts at 6 months (n = 3) compared to about 20–80 for the Propaten® grafts (n = 3), which have less than one-half the diameter, a 6-fold higher pressure gradient, and stunted vascular development downstream of the graft. The engineered grafts exhibit a stable diameter over months 12–18 when the lambs become adult sheep (n = 2). Conclusions This study supports the use of these regenerative grafts with somatic growth capacity for clinical trial in patients born with a unilateral absent pulmonary artery branch, and it shows their potential for improving development of the downstream pulmonary vasculature.
- 16 October 2024
- Published by Springer Nature in Communications Medicine
- Vol. 4 (1) , 1-12
Open AccessEvaluation of an engineered vascular graft exhibiting somatic growth in lambs to model repair of absent pulmonary artery branch
Background Growth is the holy grail of tissue implants in pediatrics. No vascular graft currently in use for surgical repairs of congenital heart defects has somatic growth capacity. Methods Biologically-engineered grafts (6 mm) grown from donor ovine fibroblasts in a sacrificial fibrin gel were implanted into the left pulmonary branch of 3-month old lambs for 3, 6, and 18 months. A control group of Propaten® PTFE grafts was implanted for 6 months. Results The engineered grafts exhibit extensive site-appropriate recellularization after only 3 months and near-normal increase of diameter from the preimplant value of 6 mm to 12.9 mm and also a doubling of length from 6.0 mm to 13.0 mm at 6 months (n = 3) associated with apparent somatic graft growth (collagen content increase of 265% over 18-month, n = 2), along with excellent hemodynamics and no calcification, in contrast to the Propaten® grafts. The left-right flow distribution is nearly 50–50 for the engineered grafts at 6 months (n = 3) compared to about 20–80 for the Propaten® grafts (n = 3), which have less than one-half the diameter, a 6-fold higher pressure gradient, and stunted vascular development downstream of the graft. The engineered grafts exhibit a stable diameter over months 12–18 when the lambs become adult sheep (n = 2). Conclusions This study supports the use of these regenerative grafts with somatic growth capacity for clinical trial in patients born with a unilateral absent pulmonary artery branch, and it shows their potential for improving development of the downstream pulmonary vasculature.
- 9 March 2023
- Published by SAGE Publications in The Journal of Vascular Access
- Vol. 25 (4) , 1271-1278
First-in-human evaluation of a biological regenerative vascular conduit for hemodialysis access
Introduction: The long-term survival and low complication rate of autogenous fistulas for hemodialysis access is often offset by early thrombosis and slow or failed maturation leading to the use of central venous catheters. A regenerative material may have the potential to overcome these limitations. A completely biological acellular vascular conduit was investigated in this first-in-human clinical study. Methods: With approval of the ethics board and patients’ informed consent, five subjects were enrolled based on predetermined inclusion criteria. Five patients underwent implant of a novel acellular, biological tissue conduit (TRUE AVC™) in the upper arm in a curved configuration between brachial artery and axillary vein. After maturation, standard dialysis was commenced through the new access. Patients were followed up to 26 weeks with ultrasound and physical exam. Serum samples were evaluated for an immune response to the novel allogeneic human tissue implant. Results: This new tissue conduit handled well surgically, with properties similar to that of native human vein. Post procedure conduit flow was excellent in all cases, averaging 1098 ± 388 ml/min at week 4 and remaining stable through 1248 ± 355 ml/min at 26 weeks. Surgical site healing was normal with no edema or erythema by week 4. Six-month primary assisted patency was 80% and secondary patency was 100%. Prescribed dialysis was successfully delivered without infection, and there was no significant change in conduit diameter. Serum testing showed no increase in PRA or IgG specific to the TRUE AVC. One implant required intervention at 5 months with thrombectomy and covered stent procedure. Conclusion: This first-in-human 6-month study with favorable patency and low complication rate establishes the initial safety and feasibility of this novel biological tissue conduit for dialysis access in patients with end-stage kidney disease. Its mechanical durability and lack of immune response establishes TRUE AVC as a potential regenerative material for clinical use.
- 9 March 2023
- Published by SAGE Publications in The Journal of Vascular Access
- Vol. 25 (4) , 1271-1278
First-in-human evaluation of a biological regenerative vascular conduit for hemodialysis access
Introduction: The long-term survival and low complication rate of autogenous fistulas for hemodialysis access is often offset by early thrombosis and slow or failed maturation leading to the use of central venous catheters. A regenerative material may have the potential to overcome these limitations. A completely biological acellular vascular conduit was investigated in this first-in-human clinical study. Methods: With approval of the ethics board and patients’ informed consent, five subjects were enrolled based on predetermined inclusion criteria. Five patients underwent implant of a novel acellular, biological tissue conduit (TRUE AVC™) in the upper arm in a curved configuration between brachial artery and axillary vein. After maturation, standard dialysis was commenced through the new access. Patients were followed up to 26 weeks with ultrasound and physical exam. Serum samples were evaluated for an immune response to the novel allogeneic human tissue implant. Results: This new tissue conduit handled well surgically, with properties similar to that of native human vein. Post procedure conduit flow was excellent in all cases, averaging 1098 ± 388 ml/min at week 4 and remaining stable through 1248 ± 355 ml/min at 26 weeks. Surgical site healing was normal with no edema or erythema by week 4. Six-month primary assisted patency was 80% and secondary patency was 100%. Prescribed dialysis was successfully delivered without infection, and there was no significant change in conduit diameter. Serum testing showed no increase in PRA or IgG specific to the TRUE AVC. One implant required intervention at 5 months with thrombectomy and covered stent procedure. Conclusion: This first-in-human 6-month study with favorable patency and low complication rate establishes the initial safety and feasibility of this novel biological tissue conduit for dialysis access in patients with end-stage kidney disease. Its mechanical durability and lack of immune response establishes TRUE AVC as a potential regenerative material for clinical use.
- 16 April 2021
- Published by Elsevier in Journal of the Mechanical Behavior of Biomedical Materials
- Vol. 119, 104527
Evaluation of the probe burst test as a measure of strength for a biologically-engineered vascular graft
- 16 April 2021
- Published by Elsevier in Journal of the Mechanical Behavior of Biomedical Materials
- Vol. 119, 104527
Evaluation of the probe burst test as a measure of strength for a biologically-engineered vascular graft
- 17 March 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 13 (585)
Pediatric tri-tube valved conduits made from fibroblast-produced extracellular matrix evaluated over 52 weeks in growing lambs
A pulmonary replacement valve made from three tubes of cell-derived matrix functioned for 52 weeks in lambs and calcified less than commercial valves.
- 17 March 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 13 (585)
Pediatric tri-tube valved conduits made from fibroblast-produced extracellular matrix evaluated over 52 weeks in growing lambs
A pulmonary replacement valve made from three tubes of cell-derived matrix functioned for 52 weeks in lambs and calcified less than commercial valves.
- 1 November 2017
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 9 (414)
A completely biological “off-the-shelf” arteriovenous graft that recellularizes in baboons
A decellularized tissue tube grown from human skin cells and fibrin becomes repopulated by recipient cells when tested in baboons as a vascular graft for hemodialysis access.
- 1 November 2017
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 9 (414)
A completely biological “off-the-shelf” arteriovenous graft that recellularizes in baboons
A decellularized tissue tube grown from human skin cells and fibrin becomes repopulated by recipient cells when tested in baboons as a vascular graft for hemodialysis access.